Scientists test new drug duo in fight against tough cancers
NCT ID NCT02159989
Summary
This early-stage study aimed to find the safest dose of two drugs, sapanisertib and ziv-aflibercept, when given together to patients with advanced solid tumors that had stopped responding to standard treatments. The main goal was to understand the side effects and determine the highest dose patients could tolerate. Researchers also looked for early signs that the drug combination could shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.